Dr. Miller completed his undergraduate degree in biology at Stanford University, where he was active in development of microsurgical devices with the Department of Ophthalmology under the mentorship of Daniel Palanker, PhD and Mark Blumenkranz, MD. He completed his MD and PhD graduate work at University of California, San Francisco (UCSF), where he developed primary neuronal culture models of Huntington's disease under the mentorship of Steve Finkbeiner at the UCSF-affiliated Gladstone Institute of Neurological Disease. He completed his internal medicine internship in the Bay Area at Kaiser Permanente Oakland. Seeking to combine his post-graduate medical and scientific training, he became the inaugural awardee for the University of Michigan Kellogg Eye Center's Pre-Residency Research Fellowship. This fellowship allowed for establishment of an independent research program prior to joining the ophthalmology residency. He completed the fellowship in 2016, joining the residency program in July 2016 and finishing in June 2019. He is currently a medical retina and research fellow at the Kellogg Eye Center. His research program, which seeks to establish primary RPE culture models of dry AMD as a platform for testing therapeutic interventions, continues during fellowship through the help of lab members he previously trained. Numerous projects exist in the lab for interested residents or medical students.
Outside of work, Dr. Miller enjoys squash (co-founding the Stanford Squash intercollegiate program while an undergraduate), foreign policy debates (co-founding a national organization dedicated to addressing human rights violations in Sudan), cooking with his wife, and watching his three young children grow up.
Areas of Interest
Primary RPE culture models of dry macular degeneration; autophagy; RPE lipid biology
Age-related macular degeneration (ARMD) is the leading cause of blindness in the developed world. The disease comes in two forms - a slowly progressive degeneration called dry ARMD and a much more rapidly progressive degeneration involving abnormal blood vessel growth called wet ARMD. In the past 10-15 years, anti-blood vessel agents have led to a radical improvement in our ability to save vision in wet ARMD patients. However, for the 80+% of patients with dry ARMD, we lack any proven therapeutic intervention. We study the mechanisms driving dry ARMD.
Macular degeneration affects the retina, the layers of cells in the back of the eye that turn light into electrical signals that the brain can interpret. Humans and primates are unique in the structure and properties of their retina, and it has therefore been difficult to establish non-primate animal models of ARMD that truly recapitulate all features of the disease. We therefore seek to use cells that we collect from human retinas to build a model of ARMD in a culture dish. The cells most affected in macular degeneration come from a pigmented layer of the retina called the retinal pigment epithelium (RPE). Our experiments involve stressing human RPE grown in the lab with a range of insults (including the insult of just carrying out routine daily activities but over a prolonged period of time), testing whether the RPE responds to the stress in a way that looks like the human disease. In particular, the cells on top of the RPE, called photoreceptors, undergo a daily shedding of their cell tip. These jettisoned fatty debris are cleared each day by the RPE. At the same time, lipid complexes enter the RPE from a set of tiny blood vessels underneath the RPE, called the choroid. These two lipid sources, photoreceptor tips and lipid particles from the blood stream, are an enormous burden to the RPE. Indeed, when the RPE loses its ability to efficiently clear this lipid load, the debris can accumulate inside and outside the RPE as "cellular trash," a first sign of dry ARMD. The trash outside the cell is called “drusen” (Figure 1). The trash inside the cell is called “lipofuscin” (Figure 2), and it can eventually consume more than 50% of the cell’s volume.
In our model system, we feed our RPE cultures photoreceptor cell tips +/- fats that mimic lipid coming from the choroidal vessels, and track how the RPE successfully and unsuccessfully handles this fatty cargo. We are also manipulating RPE pathways involved in metabolism and cellular trash removal to improve the RPE's ability to handle photoreceptor cell tips or toxic debris. To date, we have found an FDA-approved compound that turns on one of the cell’s “trash removal” systems, termed autophagy, and non-toxically reduces lipofuscin accumulation and secretion of a major component of drusen, termed APOE. This drug may be a therapeutic candidate for dry AMD. Ongoing manipulations of other lipid handling pathways should reveal additional drugs that improve the RPE's ability to "handle its trash" and therefore slow dry ARMD progression.
- Qitao Zhang, PhD, Postdoctoral Research Fellow
- Feriel Presswalla, BS, Research Lab Specialist Associate
Honors & Awards
- Evangelos S. Gragoudas Award and Lecture, Macula Society
- Fellow Research Retreat, Association of University Professors of Ophthalmology (AUPO), 2019
- George Slocum Resident Research Award, U-M Kellogg Eye Center, 2019
- Heed Fellow, appointed by The Heed Ophthalmic Foundation and the Society of Heed Fellows, 2019
- LaBerge Award for research on macular degeneration, 2018
- Resident and Fellow Research Forum Awardee, Association of University Professors of Ophthalmology (AUPO)/Research to Prevent Blindness (RPB)
- Resident Research Award, The Michigan Society of Eye Physicians and Surgeons (MiSEPS)
- Selected to attend the prestigious Heed Foundation Residents Retreat. Dr. Miller is one of 35-40 residents nationwide, nominated by their residency director or department chair, selected to attend the retreat.
- MD - University of California, San Francisco
- PhD - University of California, San Francisco
- Residency - Ophthalmology, Kellogg Eye Center, University of Michigan
- Postdoctoral Fellow, Kellogg Eye Center, University of Michigan
- Kellogg Eye Center Pre-Residency Research Fellowship
- International Retinal Research Foundation
- VitreoRetinal Surgery Foundation